298 related articles for article (PubMed ID: 21473899)
21. Neuroprotective Mechanisms Mediated by CDK5 Inhibition.
Mushtaq G; Greig NH; Anwar F; Al-Abbasi FA; Zamzami MA; Al-Talhi HA; Kamal MA
Curr Pharm Des; 2016; 22(5):527-34. PubMed ID: 26601962
[TBL] [Abstract][Full Text] [Related]
22. A review on cyclin-dependent kinase 5: An emerging drug target for neurodegenerative diseases.
Batra S; Jahan S; Ashraf A; Alharby B; Jawaid T; Islam A; Hassan I
Int J Biol Macromol; 2023 Mar; 230():123259. PubMed ID: 36641018
[TBL] [Abstract][Full Text] [Related]
23. Cdk5-p25 as a key element linking amyloid and tau pathologies in Alzheimer's disease: Mechanisms and possible therapeutic interventions.
Maitra S; Vincent B
Life Sci; 2022 Nov; 308():120986. PubMed ID: 36152679
[TBL] [Abstract][Full Text] [Related]
24. Protocols for Characterization of Cdk5 Kinase Activity.
Terse A; Amin N; Hall B; Bhaskar M; B K B; Utreras E; Pareek TK; Pant H; Kulkarni AB
Curr Protoc; 2021 Oct; 1(10):e276. PubMed ID: 34679246
[TBL] [Abstract][Full Text] [Related]
25. Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer's disease.
Monaco EA
Curr Alzheimer Res; 2004 Feb; 1(1):33-8. PubMed ID: 15975083
[TBL] [Abstract][Full Text] [Related]
26. Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity.
Chen J; Li S; Sun W; Li J
PLoS One; 2015; 10(4):e0123864. PubMed ID: 25875370
[TBL] [Abstract][Full Text] [Related]
27. Regulation and role of cyclin-dependent kinase activity in neuronal survival and death.
Hisanaga S; Endo R
J Neurochem; 2010 Dec; 115(6):1309-21. PubMed ID: 21044075
[TBL] [Abstract][Full Text] [Related]
28. p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease.
Hallows JL; Iosif RE; Biasell RD; Vincent I
J Neurosci; 2006 Mar; 26(10):2738-44. PubMed ID: 16525053
[TBL] [Abstract][Full Text] [Related]
29. Cdk5 in the adult non-demented brain.
Fischer A; Sananbenesi F; Spiess J; Radulovic J
Curr Drug Targets CNS Neurol Disord; 2003 Dec; 2(6):375-81. PubMed ID: 14683465
[TBL] [Abstract][Full Text] [Related]
30. Cyclin-dependent kinases in brain development and disease.
Su SC; Tsai LH
Annu Rev Cell Dev Biol; 2011; 27():465-91. PubMed ID: 21740229
[TBL] [Abstract][Full Text] [Related]
31. Cdk5 activity in the brain - multiple paths of regulation.
Shah K; Lahiri DK
J Cell Sci; 2014 Jun; 127(Pt 11):2391-400. PubMed ID: 24879856
[TBL] [Abstract][Full Text] [Related]
32. Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses.
Wilkaniec A; Czapski GA; Adamczyk A
J Neurochem; 2016 Jan; 136(2):222-33. PubMed ID: 26376455
[TBL] [Abstract][Full Text] [Related]
33. CDK5-mediated phosphorylation of p19INK4d avoids DNA damage-induced neurodegeneration in mouse hippocampus and prevents loss of cognitive functions.
Ogara MF; Belluscio LM; de la Fuente V; Berardino BG; Sonzogni SV; Byk L; Marazita M; Cánepa ET
Biochim Biophys Acta; 2014 Jul; 1843(7):1309-24. PubMed ID: 24703879
[TBL] [Abstract][Full Text] [Related]
34. Cdk5 and aberrant cell cycle activation at the core of neurodegeneration.
Requejo-Aguilar R
Neural Regen Res; 2023 Jun; 18(6):1186-1190. PubMed ID: 36453392
[TBL] [Abstract][Full Text] [Related]
35. Cyclin-dependent kinase 5 activators p35 and p39 facilitate formation of functional synapses.
Johansson JU; Lilja L; Chen XL; Higashida H; Meister B; Noda M; Zhong ZG; Yokoyama S; Berggren PO; Bark C
Brain Res Mol Brain Res; 2005 Aug; 138(2):215-27. PubMed ID: 15908038
[TBL] [Abstract][Full Text] [Related]
36. Deregulation of cdk5 in Hippocampal sclerosis.
Sen A; Thom M; Martinian L; Jacobs T; Nikolic M; Sisodiya SM
J Neuropathol Exp Neurol; 2006 Jan; 65(1):55-66. PubMed ID: 16410749
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein.
Binukumar BK; Shukla V; Amin ND; Bhaskar M; Skuntz S; Steiner J; Winkler D; Pelech SL; Pant HC
J Alzheimers Dis; 2015; 48(4):1009-17. PubMed ID: 26444778
[TBL] [Abstract][Full Text] [Related]
38. Cyclin-dependent kinase 5 (CDK5) and neuronal cell death.
Weishaupt JH; Neusch C; Bähr M
Cell Tissue Res; 2003 Apr; 312(1):1-8. PubMed ID: 12684868
[TBL] [Abstract][Full Text] [Related]
39. A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons.
Zheng YL; Kesavapany S; Gravell M; Hamilton RS; Schubert M; Amin N; Albers W; Grant P; Pant HC
EMBO J; 2005 Jan; 24(1):209-20. PubMed ID: 15592431
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylation of p35 and p39 by Cdk5 determines the subcellular location of the holokinase in a phosphorylation-site-specific manner.
Asada A; Saito T; Hisanaga S
J Cell Sci; 2012 Jul; 125(Pt 14):3421-9. PubMed ID: 22467861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
